Antibe Therapeutics Inc (CVE:ATE) (OTCMKTS:ATBPF) said Friday that the last patient has been enrolled and is on treatment in the Phase 2B dose-ranging, efficacy study of Antibe’s lead drug, ATB-346.
The study is evaluating the effectiveness of ATB-346 in reducing osteoarthritis pain compared to a placebo in 360 patients.
In a statement, the Toronto-based company said the final patients will be on treatment for two weeks, followed by a two-week monitoring period and analysis of the primary endpoint data. The primary endpoint in the study tracks the change in osteoarthritis knee pain in patients taking ATB-346, versus placebo as measured by the WOMAC subscale pain score, considered the gold standard in pain assessment for arthritis trials.
Patients have been randomized to placebo or one of three doses of ATB-346 administered once daily: 150 mg, 200 mg or 250 mg, said the company.
The company anticipates the release of top-line results within six weeks.
ATB-346 targets acute and chronic pain associated with osteoarthritis. Currently in Phase 2 trials, the drug is a naproxen-derivative that has been shown to deliver pain relief with significantly less gastrointestinal damage than typical NSAID usage.
Antibe develops safer, non-addictive medicines for pain and inflammation. The company’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce an improved medicine. In addition to ATB-346, designed to target the need for a safer, non-addictive drug for chronic pain, the company’s second pipeline drug ATB-352, targets the need for a non-addictive analgesic for treating post-surgical pain. ATB-340, meanwhile, is a GI-safe derivative of aspirin.
Contact the author Uttara Choudhury at [email protected]
Follow her on Twitter: @UttaraProactive